EGFR and prostate cancer: Wang et al. also showed a radiosensitizing effect of combined inhibition of EGFR through erlotinib and the IGF-1R inhibitor AG1024 in prostate cancer cells, suggesting a suppression of homologous recombination repair as a possible underlying mechanism (32).